Wealth Quarterback LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 56.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,565 shares of the company's stock after selling 9,774 shares during the quarter. Johnson & Johnson accounts for about 0.7% of Wealth Quarterback LLC's investment portfolio, making the stock its 28th biggest holding. Wealth Quarterback LLC's holdings in Johnson & Johnson were worth $1,255,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the business. Lantz Financial LLC grew its position in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $453,000. Joel Isaacson & Co. LLC boosted its stake in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. State of Wyoming raised its position in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares during the period. Finally, Range Financial Group LLC raised its position in Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the period. 69.55% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday. Royal Bank Of Canada lifted their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday. Wall Street Zen cut Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $172.87.
Get Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Trading Up 0.4%
NYSE:JNJ traded up $0.67 during trading hours on Friday, hitting $163.65. 9,764,459 shares of the company were exchanged, compared to its average volume of 8,141,137. The company has a fifty day simple moving average of $154.29 and a 200 day simple moving average of $155.05. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $393.75 billion, a price-to-earnings ratio of 17.50, a price-to-earnings-growth ratio of 2.08 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $2.82 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson's payout ratio is 55.61%.
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories

Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.